Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.
1. A method for treating a patient suffering from a solid cancer selected from the group consisting of colorectal cancer, lung cancer, ovarian cancer, breast cancer, cervical cancer, hepatocellular carcinoma, melanoma, and pancreatic cancer, wherein said method comprises the steps of:
i) measuring in a solid tumor sample obtained from the patient, prior to anti-cancer treatment, the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, with the proviso that said at least 7 genes comprise one or more of CD3D and GZMM;
ii) comparing every expression level determined at step i) with a corresponding predetermined reference value;
iii) selecting the patient as being a responder to at least one immunotherapeutic agent when all expression levels determined at step i) are either higher or lower than the corresponding predetermined reference value; and
iv) administering said immunotherapeutic agent to said patient assessed as being a responder thereto in step iii),
wherein said at least one immunotherapeutic agent is an antibody selected from the group consisting of
an antibody directed against any one of CTLA4, PD1, PDL1, TIM3, LAG3, B7H3, B7H4, TREM, BTLA, LIGHT, B7H6, and any combination thereof.
2. The method according to claim 1 , wherein the gene expression level of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21 is measured at step i).
3. The method according to claim 2 , wherein the solid cancer is non-metastatic colorectal cancer, and wherein it is further concluded at step iii) that the patient will significantly respond to the treatment when all expression levels determined at step i) are higher than the corresponding predetermined reference value.
4. The method according to claim 2 , wherein the solid cancer is metastatic colorectal cancer, and wherein it is further concluded at step iii) that the patient will significantly respond to the treatment when all expression levels determined at step i) are lower than the corresponding predetermined reference value.
5. The method according to claim 2 , wherein the solid cancer is metastatic lung cancer, and wherein it is further concluded at step iii) that the patient will significantly respond to the treatment when all expression levels determined at step i) are lower than the corresponding predetermined reference value.
6. The method according to claim 2 , wherein the solid cancer is metastatic ovarian cancer, and wherein it is further concluded at step iii) that the patent will significantly respond to the treatment when all expression levels determined at step i) are higher than the corresponding predetermined reference value.